Flush with AZ cash, Almirall seeks dermatology assets
This article was originally published in Scrip
Almirall has fresh funds and wants to spend them on acquiring new dermatology assets, CEO Eduardo Sanchiz said following the surprise announcement that the Spanish firm is to sell its respiratory portfolio to AstraZeneca.
You may also be interested in...
Peter Guenter has steadied the ship at Almirall, and after seven months in the role he outlines his vision for the company in his first exclusive interview as CEO of Spain's largest pharma company.
AbbVie’s Humira has been the world’s best-selling drug since 2012, and if it hadn’t been for COVID-19 it would most likely have been on track to retain its position for the 10th year in row.
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.